165 related articles for article (PubMed ID: 18192244)
1. Introduction. Update on pharmaceutical reimbursement and implications for health-system pharmacists .
Johnson PE
Am J Health Syst Pharm; 2008 Jan; 65(2 Suppl 1):S2-3. PubMed ID: 18192244
[No Abstract] [Full Text] [Related]
2. Pharmaceutical reimbursement: an overview.
Johnson PE
Am J Health Syst Pharm; 2008 Jan; 65(2 Suppl 1):S4-10. PubMed ID: 18192246
[TBL] [Abstract][Full Text] [Related]
3. Current issues in pharmaceutical reimbursement.
Fijalka S; Fye D; Johnson PE
Am J Health Syst Pharm; 2008 Jan; 65(2 Suppl 1):S11-26. PubMed ID: 18192243
[TBL] [Abstract][Full Text] [Related]
4. Incentives in the Medicare prescription drug benefit.
Natl Bur Econ Res Bull Aging Health; 2006; (15):1-2. PubMed ID: 16805056
[No Abstract] [Full Text] [Related]
5. Don't exclude community pharmacists.
Hoey BD
Mod Healthc; 2014 Mar; 44(10):26. PubMed ID: 24830277
[No Abstract] [Full Text] [Related]
6. Billing for Medicare Part D vaccines.
Moore KJ
Fam Pract Manag; 2007; 14(7):33-4. PubMed ID: 17696056
[No Abstract] [Full Text] [Related]
7. Pharmacists, Medicare Part D, and the antikickback statute.
Greene A
Am J Health Syst Pharm; 2006 Aug; 63(15):1435-7. PubMed ID: 16849708
[No Abstract] [Full Text] [Related]
8. Medicare physician payment: 2007 cut and proposed changes to fee schedule methodology.
S D Med; 2006 Aug; 59(8):351. PubMed ID: 16941853
[No Abstract] [Full Text] [Related]
9. The challenge of Medicare Part D for community pharmacies.
Stone D
J Manag Care Pharm; 2009 Mar; 15(2):171-2. PubMed ID: 19236134
[No Abstract] [Full Text] [Related]
10. Practice models used by pharmacists in rural Minnesota to obtain Medicare reimbursement.
Larson TA; Uden DL; Hadsall RS
J Am Pharm Assoc (Wash); 2000; 40(4):554-9. PubMed ID: 10932466
[TBL] [Abstract][Full Text] [Related]
11. Pharmacists praise new Medicare billing opportunities: provider status still critical, they say.
Traynor K
Am J Health Syst Pharm; 2015 Jan; 72(2):91-2. PubMed ID: 25550129
[No Abstract] [Full Text] [Related]
12. Cracking the Medicare Secondary Payer Enigma Code.
Dickinson BF
Tort Trial Insur Pract Law J; 2017; 52(3):921-47. PubMed ID: 30024136
[No Abstract] [Full Text] [Related]
13. House says "yes" to Medicare Part D price negotiations, passes legislation.
Consult Pharm; 2007 Mar; 22(3):254. PubMed ID: 17691158
[No Abstract] [Full Text] [Related]
14. Basic terminology in obtaining reimbursement for pharmacists' cognitive services.
Nutescu EA; Klotz RS
Am J Health Syst Pharm; 2007 Jan; 64(2):186-92. PubMed ID: 17215470
[TBL] [Abstract][Full Text] [Related]
15. Unresolved Medicare reimbursement issues.
Stoker J
Home Healthc Nurse; 2000 May; 18(5):296. PubMed ID: 11951761
[No Abstract] [Full Text] [Related]
16. Health Care Financing Administration: Pharmaceutical Reimbursement Board; final maximum allowable cost determinations.
Fed Regist; 1979 Aug; 44(169):50651-6. PubMed ID: 10297564
[No Abstract] [Full Text] [Related]
17. Part D outdoes expectations. But providers may face more cuts in reimbursement.
DoBias M
Mod Healthc; 2006 Jul; 36(28):8-9. PubMed ID: 16898553
[No Abstract] [Full Text] [Related]
18. New rules for US drug reimbursement.
Bouchie A
Nat Biotechnol; 2003 Oct; 21(10):1119-20. PubMed ID: 14520382
[No Abstract] [Full Text] [Related]
19. Medicare Part D creates challenges for safety-net providers and law enforcement.
Young D
Am J Health Syst Pharm; 2005 Aug; 62(16):1646-50. PubMed ID: 16085924
[No Abstract] [Full Text] [Related]
20. Medicaid cites persistent problems with pharmacy claims.
Landis NT
Am J Health Syst Pharm; 2000 Apr; 57(7):638. PubMed ID: 10768817
[No Abstract] [Full Text] [Related]
[Next] [New Search]
